A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study

The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with...

Descripción completa

Detalles Bibliográficos
Autores: Martínez-Trufero, Javier, De Sande-González, Luis Miguel, Luna, Pablo, Martin-Broto, Javier, Álvarez, Rosa, Marquina, Gloria, Diaz-Beveridge, Roberto, Poveda, Andrés, Cano, Juana María, Cruz-Jurado, Josefina, López Pousa, Antonio, Vaz Salgado, María Angeles, Valverde-Morales, Claudia M., Sevilla, Isabel, Martínez-García, Jerónimo, Rubio-Casadevall, Jordi, De Juan, Ana, Carrasco, Juan Antonio, Moura, David S., Gurruchaga-Sotes, Ibon, Gutiérrez, Antonio
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18255
Acceso en línea:http://hdl.handle.net/20.500.12105/18255
Access Level:acceso abierto
Palabra clave:Trabectedin
Sarcoma
Growth modulation index
Prognostic score
L-sarcoma
GEISTRA
Spain
Advanced soft tissue sarcomas
Trabectedina
Pronóstico
Liposarcoma
Leiomiosarcoma
España
Humans
Prognosis
Retrospective Studies
Thiamine Triphosphate
Multivariate Analysis
Leiomyosarcoma
Descripción
Sumario:The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS.

Similares en LA Referencia